BridgeBio Pharma raised about $1 billion through a preferred equity deal as it prepares for three potential drug launches over the next year. The funding is designed to bolster the company’s cash reserves ahead of anticipated commercial and regulatory milestones. BridgeBio has been moving assets through late-stage development across multiple indications, and the financing suggests management is prioritizing balance-sheet resilience to support launch readiness, manufacturing scale-up, and continued pipeline execution. For the broader sector, the transaction reflects how mid-to-late stage biotechs are using capital structures beyond traditional equity issuance to fund near-term catalysts while managing dilution risk.